Patents Assigned to THERAPEUTICS, INC.
  • Derivatives of amphotericin B
    Patent number: 10597420
    Abstract: Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3?-substituted C16 ureas, carbamates, and amides according to Formula (II); C16 acyls according to Formula (III); C2?epi-C16 ureas, carbamates, and amides according to Formula (IV); and C16 oxazolidinone derivatives according to Formula (V). Also disclosed are pharmaceutical compositions comprising the AmB derivatives, and therapeutic methods of using the AmB derivatives.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: March 24, 2020
    Assignee: Sfunga Therapeutics, Inc.
    Inventors: Martin D. Burke, Arun P. Thottumkara, Kevin T. Mellem, Zachary K. Sweeney, Elena S. Koltun
  • Selective androgen receptor degrader (SARD) ligands and methods of use thereof
    Patent number: 10597354
    Abstract: This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other 5 hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: March 24, 2020
    Assignees: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, ONCTERNAL THERAPEUTICS, INC
    Inventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Charles B. Duke, Christopher C. Coss, Amanda Jones, James T. Dalton
  • Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
    Patent number: 10597660
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: March 24, 2020
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou, Markus Hossbach, Jochen Deckert
  • Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
    Patent number: 10596158
    Abstract: Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: March 24, 2020
    Assignee: Akebia Therapeutics, Inc.
    Inventors: James Densmore Copp, Ann W. Newman, Anne Luong
  • Aryl ethers and uses thereof
    Patent number: 10597366
    Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: March 24, 2020
    Assignee: Peloton Therapeutics, Inc.
    Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
  • Combination therapy with peptide epoxyketones
    Patent number: 10596222
    Abstract: The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: March 24, 2020
    Assignee: ONYX THERAPEUTICS, INC.
    Inventors: Christopher J. Kirk, Susan D. Demo, Mark K. Bennett
  • METHODS FOR DIFFERENTIATING PLURIPOTENT STEM CELLS IN DYNAMIC SUSPENSION CULTURE
    Publication number: 20200087622
    Abstract: Methods for differentiating pluripotent stem cells to neuroectoderm in dynamic suspension culture using small molecule or protein inhibitors of TGF?/Activin/Nodal signaling and BMP signaling are provided. Also provided are methods and protocols for differentiating pluripotent stem cells such as human embryonic stem cells first to neuroectoderm, then further to glial progenitor cells, and further to oligodendrocyte progenitor cells (OPCs), and compositions obtained thereby. The methods of the present disclosure reproducibly produce neuroectoderm progenitor cells by day 7 of the differentiation process, glial progenitor cells by day 21 of the differentiation process and OPCs by day 42 of the differentiation process.
    Type: Application
    Filed: September 19, 2019
    Publication date: March 19, 2020
    Applicant: Lineage Cell Therapeutics, Inc.
    Inventors: Rekha R. Nair, Stephanie Kayser, Abhirath S. Parikh, Uzma Shoukat-Mumtaz, Erik Michael Whiteley, Nathan C. Manley, Craig R. Halberstadt
  • CONSTRUCTS TARGETING PSA PEPTIDE/MHC COMPLEXES AND USES THEREOF
    Publication number: 20200087400
    Abstract: The present application provides constructs comprising an antibody moiety that specifically binds to a complex comprising a PSA peptide and an MHC class I protein. Also provided are methods of making and using these constructs.
    Type: Application
    Filed: July 22, 2016
    Publication date: March 19, 2020
    Applicants: EUREKA THERAPEUTICS, INC., EUREKA THERAPEUTICS, INC.
    Inventors: Hong LIU, Jingyi XIANG, Yiyang XU, Vivien Wai-Fan CHAN
  • METHODS FOR MEASURING THERAPEUTIC EFFECTS OF RETINAL DISEASE THERAPIES
    Publication number: 20200085882
    Abstract: Described herein are compositions and methods for treating retinal diseases or disorders using RPE cells.
    Type: Application
    Filed: March 16, 2018
    Publication date: March 19, 2020
    Applicant: Lineage Cell Therapeutics, Inc.
    Inventors: Oscar Cuzzani, Francois Binette, Gary Hogge
  • Kinase Inhibitors and Uses Thereof
    Publication number: 20200087319
    Abstract: The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.
    Type: Application
    Filed: November 14, 2019
    Publication date: March 19, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Javier De Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Christopher R.H. Hale, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Elena Serra, Zachary K. Sweeney, Arun Thottumkara
  • GALECTIN-3 PLASMAPHERESIS THERAPY
    Publication number: 20200085867
    Abstract: The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.
    Type: Application
    Filed: November 18, 2019
    Publication date: March 19, 2020
    Applicant: ELIAZ THERAPEUTICS, INC.
    Inventor: ISAAC ELIAZ
  • IMPROVED LAMP CONSTRUCTS COMPRISING CANCER ANTIGENS
    Publication number: 20200087365
    Abstract: The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver cancer antigens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular hyperproliferative disorders and/or cancer. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs. The improved LAMP Constructs as described herein can also be used to generate antibodies when administered to a non-human vertebrate.
    Type: Application
    Filed: May 2, 2018
    Publication date: March 19, 2020
    Applicant: Immunomic Therapeutics, Inc
    Inventor: Teri Heiland
  • GALECTIN-3 PLASMAPHERESIS THERAPY
    Publication number: 20200085866
    Abstract: The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.
    Type: Application
    Filed: November 18, 2019
    Publication date: March 19, 2020
    Applicant: ELIAZ THERAPEUTICS, INC.
    Inventor: ISAAC ELIAZ
  • Factor IX polypeptide formulations
    Patent number: 10588949
    Abstract: The present invention provides formulations comprising a Factor IX-FcRn Binding Partner (FIXFBP) polypeptide, and methods of administering FIXFBP.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 17, 2020
    Assignee: Bioverativ Therapeutics Inc.
    Inventor: Mark Brader
  • Metering valve for a metered dose inhaler
    Patent number: 10589052
    Abstract: An improved aerosol dispensing apparatus includes an aerosol container, a discharge piece movably mounted to the aerosol container, a metering valve mounted within the discharge piece, a battery, and an electronically controlled flow control valve. The flow control valve is electronically connected to the battery and is in fluid communication with the metering valve. The metering valve is movable between an open position wherein a volume of an aerosol formulation is directed from the aerosol container through the metering valve to the electronically controlled flow control valve, and a closed position wherein the aerosol formulation is not permitted to flow through the metering valve. The electronically controlled flow control valve is configured to precisely control a flow of the aerosol formulation outward of the discharge piece.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: March 17, 2020
    Assignees: DunAn Microstaq, Inc., Pearl Therapeutics, Inc.
    Inventors: E. Nelson Fuller, Parthiban Arunasalam, Joseph Nguyen, Joe A. Ojeda, Sr., Wayne Curtis Long, Michael Thomas Riebe, Matthew Skelly Ferriter, Jill Karen Sherwood, Daniel Marion Deaton, III, Michael Leon Franklin
  • Guanidine compounds and use thereof
    Patent number: 10590081
    Abstract: The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: March 17, 2020
    Assignee: ImmunoMet Therapeutics Inc.
    Inventors: Sung Wuk Kim, Hong Woo Kim, Sang Hee Yoo, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Ji Ae Kook, Young Woo Lee
  • Benzimidazoles for use in the treatment of cancer and inflammatory diseases
    Patent number: 10590108
    Abstract: Provided herein are methods for treating, preventing, or ameliorating one or more symptoms of a condition, disorder, or disease mediated by a lipid kinase or a protein kinase with benzimidazoles, for example, of Formula I or II, and pharmaceutical compositions thereof. Also provided herein are benzimidazoles, and pharmaceutical compositions thereof; and methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: March 17, 2020
    Assignee: CAPELLA THERAPEUTICS, INC.
    Inventor: Yun Long
  • PD-L1-specific antibodies and methods of using the same
    Patent number: 10590199
    Abstract: The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: March 17, 2020
    Assignee: CHECKPOINT THERAPEUTICS, INC.
    Inventors: Jonathan Belk, Nathan J. Sharkey, Leonid Gorelik
  • Antibodies targeting G-protein coupled receptor and methods of use
    Patent number: 10590196
    Abstract: The presently disclosed subject matter provides antibodies that bind to GPRC5D and methods of using the same.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: March 17, 2020
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Eric L. Smith, Cheng Liu
  • RAD51 inhibitors
    Patent number: 10590122
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: March 17, 2020
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Casey Cameron McComas, Joseph Vacca, Tyler Maclay